Grape	0	5	B-Organism_substance
seed	6	10	I-Organism_substance
extract	11	18	I-Organism_substance
inhibits	19	27	O
angiogenesis	28	40	O
via	41	44	O
suppression	45	56	O
of	57	59	O
the	60	63	O
vascular	64	72	B-Gene_or_gene_product
endothelial	73	84	I-Gene_or_gene_product
growth	85	91	I-Gene_or_gene_product
factor	92	98	I-Gene_or_gene_product
receptor	99	107	I-Gene_or_gene_product
signaling	108	117	O
pathway	118	125	O
.	125	126	O

Blockade	128	136	O
of	137	139	O
angiogenesis	140	152	O
is	153	155	O
an	156	158	O
important	159	168	O
approach	169	177	O
for	178	181	O
cancer	182	188	B-Pathological_formation
treatment	189	198	O
and	199	202	O
prevention	203	213	O
.	213	214	O

Vascular	215	223	B-Gene_or_gene_product
endothelial	224	235	I-Gene_or_gene_product
growth	236	242	I-Gene_or_gene_product
factor	243	249	I-Gene_or_gene_product
(	250	251	O
VEGF	251	255	B-Gene_or_gene_product
)	255	256	O
is	257	259	O
one	260	263	O
of	264	266	O
the	267	270	O
most	271	275	O
critical	276	284	O
factors	285	292	O
that	293	297	O
induce	298	304	O
angiogenesis	305	317	O
and	318	321	O
has	322	325	O
thus	326	330	O
become	331	337	O
an	338	340	O
attractive	341	351	O
target	352	358	O
for	359	362	O
antiangiogenesis	363	379	O
treatment	380	389	O
.	389	390	O

However	391	398	O
,	398	399	O
most	400	404	O
current	405	412	O
anti	413	417	O
-	417	418	O
VEGF	418	422	B-Gene_or_gene_product
agents	423	429	O
often	430	435	O
cause	436	441	O
some	442	446	O
side	447	451	O
effects	452	459	O
when	460	464	O
given	465	470	O
chronically	471	482	O
.	482	483	O

Identification	484	498	O
of	499	501	O
naturally	502	511	O
occurring	512	521	O
VEGF	522	526	B-Gene_or_gene_product
inhibitors	527	537	O
derived	538	545	O
from	546	550	O
diet	551	555	O
would	556	561	O
be	562	564	O
one	565	568	O
alternative	569	580	O
approach	581	589	O
with	590	594	O
an	595	597	O
advantage	598	607	O
of	608	610	O
known	611	616	O
safety	617	623	O
.	623	624	O

Grape	625	630	B-Organism_substance
seed	631	635	I-Organism_substance
extract	636	643	I-Organism_substance
(	644	645	O
GSE	645	648	B-Organism_substance
)	648	649	O
,	649	650	O
a	651	652	O
widely	653	659	O
used	660	664	O
dietary	665	672	O
supplement	673	683	O
,	683	684	O
is	685	687	O
known	688	693	O
to	694	696	O
have	697	701	O
antitumor	702	711	B-Pathological_formation
activity	712	720	O
.	720	721	O

In	722	724	O
this	725	729	O
study	730	735	O
,	735	736	O
we	737	739	O
have	740	744	O
explored	745	753	O
the	754	757	O
activity	758	766	O
of	767	769	O
GSE	770	773	B-Organism_substance
on	774	776	O
VEGF	777	781	B-Gene_or_gene_product
receptor	782	790	I-Gene_or_gene_product
and	791	794	O
angiogenesis	795	807	O
.	807	808	O

We	809	811	O
found	812	817	O
that	818	822	O
GSE	823	826	B-Organism_substance
could	827	832	O
directly	833	841	O
inhibit	842	849	O
the	850	853	O
kinase	854	860	O
activity	861	869	O
of	870	872	O
purified	873	881	O
VEGF	882	886	B-Gene_or_gene_product
receptor	887	895	I-Gene_or_gene_product
2	896	897	I-Gene_or_gene_product
,	897	898	O
a	899	900	O
novel	901	906	O
activity	907	915	O
of	916	918	O
GSE	919	922	B-Organism_substance
that	923	927	O
has	928	931	O
not	932	935	O
been	936	940	O
characterized	941	954	O
.	954	955	O

GSE	956	959	B-Organism_substance
could	960	965	O
also	966	970	O
inhibit	971	978	O
the	979	982	O
VEGF	983	987	B-Gene_or_gene_product
receptor	988	996	I-Gene_or_gene_product
/	996	997	O
mitogen	997	1004	B-Gene_or_gene_product
-	1004	1005	I-Gene_or_gene_product
activated	1005	1014	I-Gene_or_gene_product
protein	1015	1022	I-Gene_or_gene_product
kinase	1023	1029	I-Gene_or_gene_product
-	1029	1030	O
mediated	1030	1038	O
signaling	1039	1048	O
pathway	1049	1056	O
in	1057	1059	O
endothelial	1060	1071	B-Cell
cells	1072	1077	I-Cell
.	1077	1078	O

As	1079	1081	O
a	1082	1083	O
result	1084	1090	O
,	1090	1091	O
GSE	1092	1095	B-Organism_substance
could	1096	1101	O
inhibit	1102	1109	O
VEGF	1110	1114	B-Gene_or_gene_product
-	1114	1115	O
induced	1115	1122	O
endothelial	1123	1134	B-Cell
cell	1135	1139	I-Cell
proliferation	1140	1153	O
and	1154	1157	O
migration	1158	1167	O
as	1168	1170	O
well	1171	1175	O
as	1176	1178	O
sprout	1179	1185	B-Tissue
formation	1186	1195	O
from	1196	1200	O
aorta	1201	1206	B-Multi-tissue_structure
ring	1207	1211	I-Multi-tissue_structure
.	1211	1212	O

In	1213	1215	O
vivo	1216	1220	O
assay	1221	1226	O
further	1227	1234	O
showed	1235	1241	O
that	1242	1246	O
GSE	1247	1250	B-Organism_substance
could	1251	1256	O
inhibit	1257	1264	O
tumor	1265	1270	B-Pathological_formation
growth	1271	1277	O
and	1278	1281	O
tumor	1282	1287	B-Pathological_formation
angiogenesis	1288	1300	O
of	1301	1303	O
MDA	1304	1307	B-Cell
-	1307	1308	I-Cell
MB	1308	1310	I-Cell
-	1310	1311	I-Cell
231	1311	1314	I-Cell
breast	1315	1321	I-Cell
cancer	1322	1328	I-Cell
cells	1329	1334	I-Cell
in	1335	1337	O
mice	1338	1342	B-Organism
.	1342	1343	O

Consistent	1344	1354	O
with	1355	1359	O
the	1360	1363	O
in	1364	1366	O
vitro	1367	1372	O
data	1373	1377	O
,	1377	1378	O
GSE	1379	1382	B-Organism_substance
treatment	1383	1392	O
of	1393	1395	O
tumor	1396	1401	B-Pathological_formation
-	1401	1402	O
bearing	1402	1409	O
mice	1410	1414	B-Organism
led	1415	1418	O
to	1419	1421	O
concomitant	1422	1433	O
reduction	1434	1443	O
of	1444	1446	O
blood	1447	1452	B-Multi-tissue_structure
vessel	1453	1459	I-Multi-tissue_structure
density	1460	1467	O
and	1468	1471	O
phosphorylation	1472	1487	O
of	1488	1490	O
mitogen	1491	1498	B-Gene_or_gene_product
-	1498	1499	I-Gene_or_gene_product
activated	1499	1508	I-Gene_or_gene_product
protein	1509	1516	I-Gene_or_gene_product
kinase	1517	1523	I-Gene_or_gene_product
.	1523	1524	O

Depletion	1525	1534	O
of	1535	1537	O
polyphenol	1538	1548	B-Drug_or_compound
with	1549	1553	O
polyvinylpyrrolidone	1554	1574	B-Drug_or_compound
abolished	1575	1584	O
the	1585	1588	O
antiangiogenic	1589	1603	O
activity	1604	1612	O
of	1613	1615	O
GSE	1616	1619	B-Organism_substance
,	1619	1620	O
suggesting	1621	1631	O
a	1632	1633	O
water	1634	1639	O
-	1639	1640	O
soluble	1640	1647	O
fraction	1648	1656	O
of	1657	1659	O
polyphenol	1660	1670	B-Drug_or_compound
in	1671	1673	O
GSE	1674	1677	B-Organism_substance
is	1678	1680	O
responsible	1681	1692	O
for	1693	1696	O
the	1697	1700	O
antiangiogenic	1701	1715	O
activity	1716	1724	O
.	1724	1725	O

Taken	1726	1731	O
together	1732	1740	O
,	1740	1741	O
this	1742	1746	O
study	1747	1752	O
indicates	1753	1762	O
that	1763	1767	O
GSE	1768	1771	B-Organism_substance
is	1772	1774	O
a	1775	1776	O
well	1777	1781	O
-	1781	1782	O
tolerated	1782	1791	O
and	1792	1795	O
inexpensive	1796	1807	O
natural	1808	1815	O
VEGF	1816	1820	B-Gene_or_gene_product
inhibitor	1821	1830	O
and	1831	1834	O
could	1835	1840	O
potentially	1841	1852	O
be	1853	1855	O
useful	1856	1862	O
in	1863	1865	O
cancer	1866	1872	B-Pathological_formation
prevention	1873	1883	O
or	1884	1886	O
treatment	1887	1896	O
.	1896	1897	O

